Independent documentation of veterinary responses to reported Zorbium® adverse events — compared against the FDA’s own approved labeling.
Reporting an adverse reaction to your vet should trigger documentation, concern, and a report to the FDA and manufacturer. In case after case, owners tell us it triggers something else: denial. This page collects what veterinarians have actually said to owners who reported a reaction — set directly against what the FDA’s own approval documents say is known, expected, and studied.
The Pattern
Across submitted cases, a theme recurs: when an owner reports a reaction, the response from the veterinary side is often to minimize, dismiss, or deny — rather than to document, report, or investigate. Below are statements we have on record, shown next to what the FDA’s approved labeling and clinical trial data actually say.
🚩 “It’s normal.”
What was reported: An owner reported a severe reaction following Zorbium® administration. The vet characterized the reaction as normal and unremarkable.
What the FDA data actually shows: Zorbium®’s own clinical trial data documents hyperthermia in the large majority of treated cats (up to 74.3%, with temperatures reaching 104°F), along with documented dysphoria, agitation, and mydriasis. These are labeled, studied adverse reactions — not the same thing as reactions being minor, expected-and-fine, or not worth monitoring closely.
🚩 “It could not possibly be the Zorbium®.”
What was reported: A cat with pre-existing cardiac and kidney disease developed a severe reaction after Zorbium administration, requiring emergency fluid therapy, which — due to the cat’s existing conditions — led to fluid overload, fluid around the heart and lungs, a multi-day hospitalization at a veterinary teaching hospital, and lifelong cardiac/renal medication. When the reaction was reported to the treating vet, she stated it could not possibly be related to the drug and did not order any workup to investigate or rule it out.
What the FDA data actually shows: Buprenorphine’s cardiovascular and temperature-regulation effects are documented in the approved label. A flat denial with no diagnostic workup is not a clinical finding — it’s an assumption, made without testing, in a case where the manufacturer itself later confirmed the drug had been dispensed and used in a manner it says should never happen (see below).
🚩 “There must have been an underlying cancer that never showed up on scans.”
What was reported: An owner reports the drug was never disclosed as an opioid, and risks were never discussed before or after administration. Their cat went into sudden cardiac arrest. When the owner asked whether the drug could have contributed, the vet insisted the drug was safe and would not cause cardiac arrest — then proposed an undiagnosed, unscanned cancer as the explanation instead. The vet has declined to report the death as a possible drug interaction to the manufacturer or the FDA, and has not yet provided the medical records the owner has repeatedly requested.
What the FDA data actually shows: Cardiac arrest is tracked as its own distinct adverse event category in FDA reporting for this drug — it is not a hypothetical risk. A vet ruling out the labeled cardiac risk in favor of an invisible, unconfirmed alternative diagnosis — without reporting the event, and without providing the records that would let anyone else evaluate it — is a decision made without evidence, not a clinical finding.
🚩 “He’s just acting like a person on a drug high. He’ll be fine.”
What was reported: A cat sent home the same day after dental surgery and a cyst removal bolted out of his carrier and ran frantically around the house. When the owner reported this to the vet, the response was that the cat was “acting like a person on a drug high” and would be fine.
What the FDA data actually shows: The approved labeling documents a specific, named progression — from euphoria to dysphoria to distress — that can include agitation, hyper-responsiveness, sudden movements, and risk of self-injury. Frantic, uncontrolled running is not an off-hand “high” to wait out; it sits squarely inside a documented adverse reaction pattern that the label itself says can escalate. Reassurance without an exam is not the same as ruling that progression out.
A Separate, Serious Issue: No Disclosure That the Drug Is an Opioid
More than one owner in this dataset reports never being told the drug administered to their cat was an opioid at all — let alone being walked through its risks beforehand. In one case, when a cat died of sudden cardiac arrest shortly after, the practice declined to report the death as a possible drug interaction and has withheld the medical records the owner needs to investigate further.
Declining to disclose that a controlled substance is being used, and then declining to report or document a serious event afterward, is not a difference of clinical opinion — it’s an informed-consent and recordkeeping issue, and in most states an owner is entitled to their own pet’s medical records regardless of what the practice concludes about cause of death.
A Separate, Serious Issue: Take-Home Dosing
In one documented case, an owner was sent home with a tube of Zorbium® and instructed to administer it herself. When she called Elanco to report the adverse reaction, the company told her directly that Zorbium® should never be dispensed for owner self-administration — it is meant to be applied in a clinical setting shortly before a procedure, with monitoring for several hours afterward. The owner did not use the take-home dose. Had she done so, by Elanco’s own description of the risk, the outcome could have been fatal.
This is not a question of whether a side effect is severe or mild. It’s a controlled-substance handling and prescribing question — the kind a state veterinary licensing board is specifically positioned to evaluate.
If You’ve Been Told Something Similar
- Ask for it in writing. Request that any statement dismissing a possible drug connection be documented in your pet’s medical record.
- Report independently. Report the adverse event yourself — you do not need your vet’s agreement to do this.
- FDA: 1-888-FDA-VETS or fda.gov/reportanimalae
- Elanco (manufacturer): 1-888-545-5973
- Get a second opinion, ideally from a veterinary teaching hospital if one is within reasonable driving distance — several owners in this dataset report better outcomes and more thorough workups there.
- If your pet was sent home with Zorbium® for self-administration, given it without your knowledge or consent, or not told it was an opioid at all, this may be worth reporting to your state veterinary licensing board in addition to the FDA — that’s a prescribing/informed-consent issue separate from the drug’s side-effect profile.
- Request your pet’s full medical records in writing. In most states you’re entitled to them regardless of what the practice concludes about cause of death or reaction — a written request creates a paper trail if a practice delays or declines.
- Share your case. zorbiumlawsuit.com
About this page: This is an independent resource compiled from owner-submitted reports and FDA-published data. It is not affiliated with, endorsed by, or sponsored by Elanco or any other product manufacturer. We are not veterinarians. Statements attributed to veterinary staff reflect what owners have reported to us; we were not present for these conversations and cannot independently verify exact wording. Nothing on this page is medical or veterinary advice — always consult a qualified veterinarian for decisions about your pet’s care, and consult a licensed attorney for individual legal concerns.